UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063647
Receipt number R000072722
Scientific Title Validity and Feasibility Study of Measuring Serum NT-proBNP Levels Using a Self-Blood-Collection Kit
Date of disclosure of the study information 2026/11/16
Last modified on 2026/11/16 16:31:03

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Validity and Feasibility Study of Measuring Serum NT-proBNP Levels Using a Self-Blood-Collection Kit

Acronym

Validity and Feasibility Study of Measuring Serum NT-proBNP Levels Using a Self-Blood-Collection Kit

Scientific Title

Validity and Feasibility Study of Measuring Serum NT-proBNP Levels Using a Self-Blood-Collection Kit

Scientific Title:Acronym

Validity and Feasibility Study of Measuring Serum NT-proBNP Levels Using a Self-Blood-Collection Kit

Region

Japan


Condition

Condition

Heart Failure

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aims to verify, in Japanese patients with heart failure, the validity of measuring serum NT-proBNP concentrations using a self-blood-collection kit compared with conventional testing methods; to assess whether the self-blood-collection kit is acceptable; and to determine whether there is any significant discrepancy between the results obtained from blood samples collected at home and sent to a testing center, and the heart failure status estimated through self-monitoring.

Basic objectives2

Others

Basic objectives -Others

Validation of a measurement method (agreement of measured values) and assessment of feasibility

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Agreement of blood NT-proBNP concentration between the specimen obtained with the self-blood-collection device and the specimen obtained by conventional venipuncture at the same time point. Agreement is assessed for the pair of specimen 1 (venipuncture) and specimen 2 (self-collection under supervision) at the first outpatient visit, and for the pair of specimen 4 (venipuncture) and specimen 5 (self-collection) at the next outpatient visit (approximately 4 to 10 weeks after consent), using Bland-Altman analysis to derive the mean difference and the 95% limits of agreement, together with the Pearson correlation coefficient.

Key secondary outcomes

1) Proportion of specimen 3 (collected at home without supervision) whose blood NT-proBNP concentration falls within the range predicted, in a blinded manner, by two independent cardiologists on the basis of patient characteristics, venipuncture NT-proBNP values before and after, and home vital sign data
2) Effect of storage and transport time: difference in measured values between specimen 5 obtained at the next outpatient visit and specimen 6 measured at least 24 hours later and specimen 7 measured at least 72 hours later
3) Specimen quality: proportion of specimens with adequate volume, and presence of hemolysis
4) Scores of a questionnaire on the feasibility of self blood collection (mental and physical burden, need for assistance by a cohabitant, subjective usefulness), and their change between supervised collection and collection at home
5) Incidence of adverse events (bleeding at the puncture site, tape-related skin irritation at the device application site, etc.)


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Device,equipment

Interventions/Control_1

This is a single-arm study in which all participants undergo the same procedures. At the first outpatient visit after consent, participants collect their own blood using a self-blood-collection device (single-use automatic lancet, TS blood collection kit, Shin Nippon Biomedical Laboratories / Tasso; approved as a medical device in Japan) under the instruction and supervision of healthcare professionals (specimen 2), at the same time as routine venipuncture performed for clinical care (specimen 1).
A blood pressure monitor, a weight scale, a thermometer and a pulse oximeter are lent to each participant, and self-monitoring is performed twice daily (morning and evening) until the next outpatient visit. During this interval, participants collect their own blood once at home without supervision (specimen 3) and complete a questionnaire on feasibility at the same time.
At the next outpatient visit (approximately 4 to 10 weeks after consent), participants collect their own blood three times using the device (specimens 5, 6 and 7) at the same time as routine venipuncture (specimen 4). Specimen 6 is measured at least 24 hours later and specimen 7 at least 72 hours later. All self-collected specimens are sent to a regional processing laboratory, where blood NT-proBNP concentration is measured.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Age 20 years or older at the time of consent
2) Outpatients attending the heart failure clinic of the Department of Cardiovascular Medicine, Juntendo University Hospital, who undergo blood sampling at every visit for heart failure management
3) Able to perform self blood collection
4) Written informed consent obtained from the participant of his or her own free will after sufficient explanation and understanding

Key exclusion criteria

1) Unable to perform self blood collection (e.g., dementia, paralysis of the extremities, skin infection, bleeding tendency)
2) Coagulation disorder
3) Otherwise judged inappropriate as a participant by the principal investigator

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Takatoshi
Middle name
Last name Kasai

Organization

Juntendo University

Division name

Department of Cardiovascular Biology and Medicine

Zip code

1138421

Address

2-1-1 Hongo Bunkyo-ku, Tokyo

TEL

03-3813-3111

Email

tkasai@juntendo.ac.jp


Public contact

Name of contact person

1st name Takatoshi
Middle name
Last name Kasai

Organization

Juntendo University

Division name

Department of Cardiovascular Biology and Medicine

Zip code

113-8421

Address

2-1-1 Hongo Bunkyo-ku, Tokyo

TEL

03-3813-3111

Homepage URL


Email

tkasai@juntendo.ac.jp


Sponsor or person

Institute

Juntendo University

Institute

Department

Personal name



Funding Source

Organization

Ministry of Education, Culture, Sports, Science and Technology

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Research Ethics Committee, Juntendo University Faculty of Medicine

Address

2-1-1Hongo, BUnkyo-ku, Tokyo

Tel

03-3813-3111

Email

tkasai@juntendo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

順天堂大学区医学部附属順天堂医院


Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 11 Month 06 Day

Date of IRB

2026 Year 11 Month 06 Day

Anticipated trial start date

2026 Year 11 Month 06 Day

Last follow-up date

2028 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2026 Year 11 Month 16 Day

Last modified on

2026 Year 11 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072722